Monte Rosa Therapeutics Announces Milestone Tied to Second Phase 2 Study
Monte Rosa Therapeutics announced a milestone achievement associated with initiation of a second Phase 2 clinical study for MRT-6160 (DDY391).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.